Bristol-Myers Squibb (BMY) return on equity (ROE)

Return on equity · fiscal 2025
38.2%

Bristol-Myers Squibb (BMY) earned a return on equity of 38.2% in fiscal 2025 (the year ended December 31, 2025). That is 93.0 percentage points higher than the -54.8% of fiscal 2024. Figures as of 17 Nov 2026, 21:43 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
38.2%
Change on fiscal 2024
+93.0 pts
Highest on record
71.5%fiscal 2009
Lowest on record
-54.8%fiscal 2024
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Bristol-Myers Squibb return on equity (ROE), in more detail

Across the 18 fiscal years on record (2008–2025), the highest was 71.5% in fiscal 2009 and the lowest -54.8% in fiscal 2024. The fiscal 2025 figure is higher than in 88% of the 17 earlier fiscal years on record, whose median is 19.5%.

History · 18 fiscal years

Return on equity by fiscal year

Bristol-Myers Squibb return on equity (ROE), year by year

Bristol-Myers Squibb (BMY) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202538.2% 93.0 pts up
2024-54.8% 82.0 pts down
202327.3% 6.9 pts up
202220.4% 0.9 pts up
202119.5% 43.3 pts up
2020-23.8% 30.5 pts down
20196.7% 28.4 pts down
201835.1% 26.5 pts up
20178.6% 19.0 pts down
201627.6% 16.6 pts up
201511.0% 2.5 pts down
201413.5% 3.4 pts down
201316.9% 2.5 pts up
201214.4% 8.9 pts down
201123.2% 3.5 pts up
201019.7% 51.8 pts down
200971.5% 28.6 pts up
200842.9%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Bristol-Myers Squibb and comparable companies
CompanyReturn on equityFiscal year
Vertex Pharmaceuticals VRTX21.2%2025
Medtronic MDT9.7%2026
Bristol-Myers Squibb BMY38.2%2025
Stryker SYK14.5%2025
McKesson MCK17.7%2020
Sanofi SNY10.9%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BMY

Bristol-Myers Squibb, figure by figure

Bristol-Myers Squibb (BMY) overview: price, valuation and scorecardAll health care companies by market value

Bristol-Myers Squibb return on equity (ROE): questions and answers

What is Bristol-Myers Squibb's return on equity?

Bristol-Myers Squibb (BMY) earned a return on equity of 38.2% in fiscal 2025 (the year ended December 31, 2025). That is 93.0 percentage points higher than the -54.8% of fiscal 2024.

Is Bristol-Myers Squibb's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 88% of the 17 earlier fiscal years on record, whose median is 19.5%.

What are the highest and lowest return on equity figures on record for Bristol-Myers Squibb?

Across the 18 fiscal years on record (2008–2025), the highest was 71.5% in fiscal 2009 and the lowest -54.8% in fiscal 2024.

How is Bristol-Myers Squibb's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Bristol-Myers Squibb (BMY) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/BMY/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.